NCT05458492View on ClinicalTrials.gov

Sirolimus in Cutaneous Sarcoidosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2022

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2027

Conditions
SarcoidosisCutaneous Sarcoidosis
Interventions
DRUG

Sirolimus

"Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks"

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER